Methods and compositions for treating cancer in taxane resistant patients

By combining ritonavir and taxane treatment, the P-gp expression level was determined and adjusted, which solved the problem of taxane resistance and improved the effectiveness and safety of cancer treatment.

CN118946350APending Publication Date: 2024-11-12MODRA PHARMACEUTICALS B V
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202380021282.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-14
Filing Date
2023-02-13
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

When long-term use of taxane to treat cancer, patients are prone to developing drug resistance, resulting in a decrease in therapeutic effectiveness, and it is difficult for the prior art to effectively reverse this drug resistance.

Method used

In combination with the use of the P-gp inhibitor ritonavir and taxane, the appropriate dose is determined and administered to reverse the cell's resistance to taxane by measuring the expression level of ABCB1 (P-gp) in patients.

Benefits of technology

Effectively reverse taxane resistance, improve the sensitivity of cancer cells to taxane, enhance the therapeutic effect, and improve the safety and control of the treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004987346570000201
    Figure BDA0004987346570000201
  • Figure BDA0004987346570000211
    Figure BDA0004987346570000211
  • Figure BDA0004987346570000221
    Figure BDA0004987346570000221
Patent Text Reader

Abstract

Methods and compositions are provided for treating cancer in a taxane resistant patient, the method comprising simultaneously or sequentially administering an effective dose of a taxane with a P-gp inhibitor, such as ritonavir, or a pharmaceutically acceptable salt thereof. Also provided are methods and compositions for reversing taxane resistance in a patient, the method comprising administering an effective dose of a P-gp inhibitor, such as ritonavir or a pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to chemotherapy of tumors using taxanes. More particularly, the present invention relates to methods and compositions for treating cancer in taxane-resistant patients using a combination of a P-gp inhibitor (such as ritonavir) and a taxane. Background Art

[0002] Treatment of cancer involves a wide range of treatments. Treatments include surgery, radiotherapy, chemotherapy, immunotherapy, and cell therapy. Typically, cancer treatments include a combination of different treatment modalities, including a combination of different therapeutic agents. Taxanes (such as docetaxel or cabazitaxel) are widely used to treat a variety of cancers as part of first-line chemotherapy.

[0003] Docetaxel is a cytotoxic agent. Its primary mode of action is understood to involve interference with microtubule assembly and disassembly, leading to inhibition of mitotic cell division. The recommended dose is 75-100 mg / m2 intravenously once every three weeks. 2 body surface area. Docetaxel is used to treat a variety of cancers, including breast cancer, lung cancer, prostate cancer, gastric cancer, head and neck cancer, and ovarian cancer. Docetaxel can be administered intravenously as a chemotherapeutic agent and is approved for the treatment of a variety of solid tumors. Variability has been observed in patients with regard to response to treatment. Improved means and methods for treating cancer with docetaxel have been proposed. In particular, docetaxel can be administered in combination with a cytochrome P450 isozyme CYP3A inhibitor, which improves the safety profile of docetaxel compared to the standard of care treatment of docetaxel.

[0004] For example, WO 2009 / 027644 A2 provides pharmaceutical compositions and methods for treating neoplastic diseases, comprising a combination of a taxane and a CYP3A4 inhibitor. WO 2020 / 127606 A1 provides cancer treatment using docetaxel (by controlling plasma levels). WO 2020 / 127607 A1 provides combined treatment of solid tumors using docetaxel and a CYP3A inhibitor.

[0005] However, despite the potential to benefit patients and improve life expectancy and quality of life, continued use of taxanes (such as docetaxel or cabazitaxel) may lead to the development of taxane resistance in patients, thereby limiting the effectiveness of taxanes in treating cancer. In addition, some patients may be refractory to taxanes from the outset, for example due to naturally high resistance. Therefore, it is highly desirable to provide a new means of treating cancer in patients with taxane resistance. Summary of the invention

[0006] Surprisingly, the inventors of the present invention have discovered that resistance to treatment with a taxane in a patient can be mitigated, substantially overcome, at least partially reversed, or substantially reversed by administering a P-gp inhibitor (i.e., ritonavir). Ritonavir can also be used to sensitize or resensitize cells to taxanes. Examples of such taxanes can include docetaxel, cabazitaxel, paclitaxel, pharmaceutically acceptable salts or esters thereof, and combinations thereof, such as for treating cancer. Examples of such cancers include solid tumors, gastric cancer, breast cancer, head and neck cancer, lung cancer, and prostate cancer.

[0007] In a first embodiment, the present invention provides a method for treating cancer in a taxane-resistant patient, the method comprising administering simultaneously or sequentially an effective dose of a taxane and ritonavir or a pharmaceutically acceptable salt thereof.

[0008] In a second embodiment, the present invention provides a method for reversing taxane resistance in a patient, the method comprising administering an effective dose of ritonavir or a pharmaceutically acceptable salt thereof.

[0009] In a third embodiment, the present invention provides a taxane for use in combination therapy with ritonavir or a pharmaceutically acceptable salt thereof to treat cancer in a taxane-resistant patient.

[0010] In a fourth embodiment, the present invention provides ritonavir or a pharmaceutically acceptable salt thereof for use in reversing taxane resistance in a patient.

[0011] In a fifth embodiment, the present invention provides a method for sensitizing or resensitizing cells to taxanes in the treatment of cancer, the method comprising administering an effective dose of ritonavir or a pharmaceutically acceptable salt thereof.

[0012] In a sixth embodiment, the present invention provides ritonavir or a pharmaceutically acceptable salt thereof for use in sensitizing or resensitizing cells to taxanes in the treatment of cancer.

[0013] In a seventh embodiment, the present invention provides a kit comprising at least one pharmaceutical composition comprising a taxane and at least one pharmaceutical composition comprising a P-gp inhibitor (such as ritonavir), wherein the kit is for use in treating cancer in a taxane-resistant patient.

[0014] In an eighth embodiment, the present invention provides a method for treating cancer, the treatment comprising a combination of a P-gp inhibitor (such as ritonavir) and a taxane, the method comprising the following steps:

[0015] Determination of ABCB1 (P-gp) expression in patients;

[0016] Optionally, comparing the expression of ABCB1 (P-gp) to a reference level;

[0017] Optionally, determining a dose of a P-gp inhibitor based on the expression level of ABCB1 (P-gp) determined in said subject;

[0018] A combination of said P-gp inhibitor and said taxane is administered. DETAILED DESCRIPTION

[0019] Specific embodiments of the present invention will now be described by way of example and with reference to the accompanying drawings, in which:

[0020] Figure 1 Docetaxel resistance in the DU145 prostate cancer cell line is shown;

[0021] Figure 2 Docetaxel resistance in the 22Rv1 prostate cancer cell line is shown;

[0022] Figure 3 P-gp protein expression in docetaxel-resistant prostate cancer cells is shown;

[0023] Figure 4 Scatter plots comparing significant genes in DU-145DOC10 and DU-145 to significant genes in 22Rv1 DOC8 and 22Rv1 are shown. The upper right sub-plot shows genes that are upregulated in both pairs. The upper left sub-plot shows genes that are upregulated in the DU-145 pair and genes that are downregulated in the 22Rv1 pair. The lower right sub-plot shows genes that are upregulated in the 22Rv1 pair and genes that are downregulated in the DU-145 pair. The lower left sub-plot shows genes that are downregulated in both pairs;

[0024] Figure 5 Ritonavir is shown to reverse docetaxel resistance in castration-resistant DU-145DOC10 prostate cancer cells (colony formation assay);

[0025] Figure 6 The combination of ritonavir and docetaxel was shown to induce a synergistic effect in docetaxel-resistant DU-145DOC10 prostate cancer cells (colony formation assay);

[0026] Figure 7 Ritonavir was shown to also reverse docetaxel resistance in 22Rv1 DOC8-resistant prostate cancer cells;

[0027] Figure 8 The combination of ritonavir and cabazitaxel was shown to induce a synergistic effect in parental DU-145 prostate cancer cells;

[0028] Fig. 9The combination of ritonavir and cabazitaxel was shown to induce a synergistic effect in docetaxel-resistant DU-145DOC10 prostate cancer cells;

[0029] Fig.10 Ritonavir is shown to reverse cabazitaxel resistance in docetaxel-resistant DU145 DOC10 prostate cancer cells;

[0030] Fig.11 The combination of ritonavir and cabazitaxel was shown to induce a synergistic effect in docetaxel-resistant 22Rv1 DOC8 prostate cancer cells;

[0031] Fig.12 Ritonavir is shown to reverse cabazitaxel resistance in docetaxel-resistant 22Rv1 DOC8 prostate cancer cells;

[0032] Fig.13 Elacrida was shown to reverse docetaxel resistance in castration-resistant DU-145DOC10 prostate cancer cells;

[0033] Fig.14 showed that elicidar and docetaxel are synergistic in docetaxel-resistant DU-145DOC10 prostate cancer cells (colony formation assay); and

[0034] Fig.15 Elacridar is shown to reverse docetaxel resistance in castration-resistant 22Rv1 DOC8 prostate cancer cells.

[0035] In a first embodiment, the present invention provides a method for treating cancer in a taxane-resistant patient, the method comprising administering simultaneously or sequentially an effective dose of a taxane and ritonavir or a pharmaceutically acceptable salt thereof.

[0036] In a second embodiment, the present invention provides a method for reversing taxane resistance in a patient, the method comprising administering an effective dose of ritonavir or a pharmaceutically acceptable salt thereof.

[0037] Herein, the terms "taxane-resistant patient" and "taxane resistance" may refer to de novo resistance (e.g., in patients who are de novo refractory to taxanes, e.g., due to having naturally higher Pg-p expression) or acquired resistance (e.g., in patients whose efficacy of taxanes decreases over time after prolonged use of taxanes (e.g., for 3 months or longer) or by increasing the dose of taxanes).

[0038] Acquired resistance to one taxane may also lead to acquired resistance to other taxanes. For example, prolonged use of docetaxel (e.g., for 3 months or longer) may lead to acquired resistance to docetaxel and / or other taxanes (e.g., cabazitaxel).

[0039] Compared with parental untreated cells, IC 50 Increased IC values ​​can identify acquired resistance in cancer cells after exposure to taxanes. 50 The increase in value can be, for example, an increase of greater than about 10 times, such as an increase of greater than about 20 times or an increase of greater than about 100 times.

[0040] Resistant cell lines (having de novo resistance or acquired resistance) can be identified by up-regulation of genes related to metabolic or homeostatic pathways compared to parental untreated cells, particularly ABCB1 (P-glycoprotein). For example, ABCB1 (P-glycoprotein) can be up-regulated by greater than about 1000 times, greater than about 2000 times, or greater than about 3000 times.

[0041] Preferably, the method is for treating cancer, wherein ritonavir or a pharmaceutically acceptable salt thereof and an effective dose of a taxane are administered simultaneously or sequentially.

[0042] For example, the cancer may include a solid tumor. For example, the cancer may be selected from the group consisting of: gastric cancer, breast cancer, head and neck cancer, lung cancer, and prostate cancer. Preferably, the cancer is prostate cancer.

[0043] The method may also include determining whether the cancer is responsive to treatment by determining the responsiveness of the DU-145 or 22Rv1 cell line to effective doses of a taxane and ritonavir or a pharmaceutically acceptable salt thereof, administered simultaneously or sequentially.

[0044] Conveniently, ritonavir and / or the taxane may be administered orally, which may provide improved means and methods for treating cancer with an improved safety profile compared to standard of care treatment with taxanes (such as docetaxel), while allowing control to be applied to obtain effective anti-tumor levels of taxane exposure. Alternatively, ritonavir and / or the taxane may be administered intravenously.

[0045] The taxane may be selected from the group consisting of docetaxel, cabazitaxel, a pharmaceutically acceptable salt or ester thereof, and combinations thereof. Preferably, the taxane is docetaxel or a pharmaceutically acceptable salt or ester thereof. Other taxanes contemplated include paclitaxel.

[0046] Ritonavir may be administered in a weekly dose of about 50 mg to about 1200 mg (eg, about 200 mg to about 400 mg).

[0047] Alternatively, ritonavir may be administered in a daily dose of about 50 mg to about 1200 mg (eg, about 100 mg to about 200 mg).

[0048] The taxane can be administered at a weekly dose of about 30 mg to about 500 mg. For example, the taxane can be docetaxel or cabazitaxel and is administered at a weekly dose of about 30 mg to about 500 mg (such as about 40 mg to about 100 mg or about 40 mg to about 50 mg).

[0049] Alternatively, the taxane may be administered at a daily dose of about 0.1 mg to about 100 mg. For example, the taxane may be docetaxel or cabazitaxel, and is administered at a daily dose of about 0.1 mg to about 100 mg (such as about 40 mg to about 50 mg).

[0050] For example, ritonavir can be administered at a daily dose of about 50 mg to about 1200 mg (such as about 100 mg to about 200 mg), and the taxane can be administered at a daily dose of about 0.1 mg to about 100 mg (such as about 40 mg to about 50 mg), wherein the daily doses of ritonavir and the taxane can be taken at the same or different times of the day.

[0051] In another example, ritonavir can be administered at a weekly dose of about 50 mg to about 1200 mg (such as about 200 mg to about 400 mg), and the taxane can be administered at a weekly dose of about 30 mg to about 500 mg (such as about 40 mg to about 100 mg or about 40 mg to about 50 mg), wherein the weekly doses of ritonavir and the taxane can be taken on the same or different days.

[0052] In a third embodiment, the present invention provides a taxane for use in combination therapy with ritonavir or a pharmaceutically acceptable salt thereof to treat cancer in a taxane-resistant patient.

[0053] Preferably, ritonavir or a pharmaceutically acceptable salt thereof and the taxane are administered simultaneously or sequentially.

[0054] For example, the cancer may include a solid tumor. For example, the cancer may be selected from the group consisting of: gastric cancer, breast cancer, head and neck cancer, lung cancer, and prostate cancer. Preferably, the cancer is prostate cancer.

[0055] The use may also include determining whether the cancer is responsive to treatment by determining the responsiveness of the DU-145 or 22Rv1 cell line to an effective dose of the combination therapy.

[0056] Conveniently, ritonavir and / or the taxane may be administered orally, which may provide improved means and methods for treating cancer with an improved safety profile compared to standard of care treatment with taxanes (such as docetaxel), while allowing control to be applied to obtain effective anti-tumor levels of taxane exposure. Alternatively, ritonavir and / or the taxane may be administered intravenously.

[0057] The taxane may be selected from the group consisting of docetaxel, cabazitaxel, a pharmaceutically acceptable salt or ester thereof, and combinations thereof. Preferably, the taxane is docetaxel or a pharmaceutically acceptable salt or ester thereof. Other taxanes contemplated include paclitaxel.

[0058] Ritonavir may be administered in a weekly dose of about 50 mg to about 1200 mg (eg, about 200 mg to about 400 mg).

[0059] Alternatively, ritonavir may be administered in a daily dose of about 50 mg to about 1200 mg (eg, about 100 mg to about 200 mg).

[0060] The taxane can be administered at a weekly dose of about 30 mg to about 500 mg. For example, the taxane can be docetaxel or cabazitaxel and is administered at a weekly dose of about 30 mg to about 500 mg (such as about 40 mg to about 100 mg or about 40 mg to about 50 mg).

[0061] Alternatively, the taxane may be administered at a daily dose of about 0.1 mg to about 100 mg. For example, the taxane may be docetaxel or cabazitaxel, and is administered at a daily dose of about 0.1 mg to about 100 mg (such as about 40 mg to about 50 mg).

[0062] For example, ritonavir can be administered at a daily dose of about 50 mg to about 1200 mg (such as about 100 mg to about 200 mg), and the taxane can be administered at a daily dose of about 0.1 mg to about 100 mg (such as about 40 mg to about 50 mg), wherein the daily doses of ritonavir and the taxane can be taken at the same or different times of the day.

[0063] In another example, ritonavir can be administered at a weekly dose of about 50 mg to about 1200 mg (such as about 200 mg to about 400 mg), and the taxane can be administered at a weekly dose of about 30 mg to about 500 mg (such as about 40 mg to about 100 mg or about 40 mg to about 50 mg), wherein the weekly doses of ritonavir and the taxane can be taken on the same or different days.

[0064] In a fourth embodiment, the present invention provides ritonavir or a pharmaceutically acceptable salt thereof for use in reversing taxane resistance in a patient.

[0065] Preferably, the use is for treating cancer in taxane-resistant patients, wherein ritonavir is administered simultaneously or sequentially with an effective dose of a taxane.

[0066] For example, the cancer may include a solid tumor. For example, the cancer may be selected from the group consisting of: gastric cancer, breast cancer, head and neck cancer, lung cancer, and prostate cancer. Preferably, the cancer is prostate cancer.

[0067] The use may include determining whether the cancer is responsive to treatment by determining the responsiveness of the DU-145 or 22Rv1 cell line to effective doses of a taxane and ritonavir or a pharmaceutically acceptable salt thereof, administered simultaneously or sequentially.

[0068] Conveniently, ritonavir and / or the taxane may be administered orally, which may provide improved means and methods for treating cancer with an improved safety profile compared to standard of care treatment with taxanes (such as docetaxel), while allowing control to be applied to obtain effective anti-tumor levels of taxane exposure. Alternatively, ritonavir and / or the taxane may be administered intravenously.

[0069] The taxane may be selected from the group consisting of docetaxel, cabazitaxel, a pharmaceutically acceptable salt or ester thereof, and combinations thereof. Preferably, the taxane may be docetaxel or a pharmaceutically acceptable salt or ester thereof. Other taxanes contemplated include paclitaxel.

[0070] Ritonavir may be administered in a weekly dose of about 50 mg to about 1200 mg (eg, about 200 mg to about 400 mg).

[0071] Alternatively, ritonavir may be administered in a daily dose of about 50 mg to about 1200 mg (eg, about 100 mg to about 200 mg).

[0072] The taxane can be administered at a weekly dose of about 30 mg to about 500 mg. For example, the taxane can be docetaxel or cabazitaxel and is administered at a weekly dose of about 30 mg to about 500 mg (such as about 40 mg to about 100 mg or about 40 mg to about 50 mg).

[0073] Alternatively, the taxane may be administered at a daily dose of about 0.1 mg to about 100 mg. For example, the taxane may be docetaxel or cabazitaxel, and is administered at a daily dose of about 0.1 mg to about 100 mg (such as about 40 mg to about 50 mg).

[0074] For example, ritonavir can be administered at a daily dose of about 50 mg to about 1200 mg (such as about 100 mg to about 200 mg), and the taxane can be administered at a daily dose of about 0.1 mg to about 100 mg (such as about 40 mg to about 50 mg), wherein the daily doses of ritonavir and the taxane can be taken at the same or different times of the day.

[0075] In another example, ritonavir can be administered at a weekly dose of about 50 mg to about 1200 mg (such as about 200 mg to about 400 mg), and the taxane can be administered at a weekly dose of about 30 mg to about 500 mg (such as about 40 mg to about 100 mg or about 40 mg to about 50 mg), wherein the weekly doses of ritonavir and the taxane can be taken on the same or different days.

[0076] In a fifth embodiment, the present invention provides a method for sensitizing or resensitizing cells to taxanes in the treatment of cancer, the method comprising administering an effective dose of ritonavir or a pharmaceutically acceptable salt thereof.

[0077] The taxane may be selected from the group consisting of docetaxel, cabazitaxel, a pharmaceutically acceptable salt or ester thereof, and combinations thereof. Preferably, the taxane is docetaxel. Other taxanes contemplated include paclitaxel.

[0078] In a sixth embodiment, the present invention provides ritonavir or a pharmaceutically acceptable salt thereof for use in sensitizing or resensitizing cells to taxanes in the treatment of cancer.

[0079] The taxane may be selected from the group consisting of docetaxel, cabazitaxel, a pharmaceutically acceptable salt or ester thereof, and combinations thereof. Preferably, the taxane is docetaxel. Other taxanes contemplated include paclitaxel.

[0080] In a seventh embodiment, the present invention provides a kit comprising at least one pharmaceutical composition comprising a taxane and at least one pharmaceutical composition comprising a P-gp inhibitor, wherein the kit is for use in treating cancer in a taxane-resistant patient.

[0081] The taxane may be selected from the group consisting of docetaxel, cabazitaxel, a pharmaceutically acceptable salt or ester thereof, and combinations thereof. Preferably, the taxane is docetaxel. Other taxanes contemplated include paclitaxel.

[0082] The P-gp inhibitor may be selected from the group consisting of ritonavir, elacridar and a combination thereof, or a pharmaceutically acceptable salt thereof. Preferably, the P-gp inhibitor is ritonavir.

[0083] The kit may comprise instructions for using the pharmaceutical composition simultaneously or sequentially to treat cancer in a taxane-resistant patient.

[0084] In an eighth embodiment, the present invention provides a method for treating cancer, said treatment comprising a combination of a P-gp inhibitor and a taxane, said method comprising the following steps:

[0085] Determination of ABCB1 (P-gp) expression in patients;

[0086] Optionally, comparing the expression of ABCB1 (P-gp) to a reference level;

[0087] Optionally, determining a dose of a P-gp inhibitor based on the expression level of ABCB1 (P-gp) determined in said subject;

[0088] The combination of a P-gp inhibitor and a taxane is administered, preferably at a dose based on the expression level of ABCB1 (P-gp) determined in the subject.

[0089] The taxane may be selected from the group consisting of docetaxel, cabazitaxel, a pharmaceutically acceptable salt or ester thereof, and combinations thereof. Preferably, the taxane is docetaxel. Other taxanes contemplated include paclitaxel.

[0090] The P-gp inhibitor may be selected from the group consisting of ritonavir, elacridar and a combination thereof, or a pharmaceutically acceptable salt thereof. Preferably, the P-gp inhibitor is ritonavir.

[0091] Furthermore, in any of the above-described embodiments of the present invention, the following features may be provided.

[0092] Oral administration of taxanes and / or ritonavir (or other P-gp inhibitors) to a subject may include any route of introducing or delivering the agent to the subject through the oral cavity to exert its intended function. Suitable pharmaceutical compositions for oral administration include liquids, tablets, or capsules. Capsules and tablets may have an enteric coating so that the taxane and / or ritonavir is released from the capsule or tablet in the intestine. Capsules and tablets may be formulated as extended release formulations so that the taxane and / or ritonavir (or other P-gp inhibitors) are released over an extended period of time, such as several hours or longer, such as during the time spent in the intestine. Thus, tablets and capsules may be formulated so that the agent is gradually released from the tablets and capsules. Tablets and capsules may be formulated so that the agent is released in the stomach or intestine. Tablets and capsules may be formulated so that the agent is released in the stomach and intestine. Administration includes self-administration and administration by others. The pharmaceutical composition of the present invention may comprise a taxane and / or ritonavir (or other P-gp inhibitors) or a pharmaceutically acceptable salt and ester thereof, together with any pharmaceutically acceptable carrier, adjuvant or vehicle. Suitable formulations and / or pharmaceutical compositions for oral administration include formulations as described in WO2009027644, WO2010020799, and Moes et al. Drug Deliv. Transl. Res. 2013, which are incorporated herein by reference in their entirety. Any suitable formulation for oral administration may be considered.

[0093] The present invention may not be limited to oral administration of taxanes and / or ritonavir (or other P-gp inhibitors). Any administration of taxanes and / or ritonavir (or other P-gp inhibitors) via the gastrointestinal tract may be considered. Therefore, enteral administration rather than oral administration may be considered herein. Preferably, enteral administration is performed in the form of capsules, tablets and suppositories. Administration of taxanes and / or ritonavir (or other P-gp inhibitors) via suppositories may be advantageous because bioavailability may be improved compared to oral administration. This is because in the case of oral administration, after passing through the stomach and intestines, taxanes and / or ritonavir (or other P-gp inhibitors) are delivered to the liver via the portal vein. By enteral administration, the obstacles of first-pass metabolism of taxanes and / or ritonavir (or other P-gp inhibitors) may be avoided. As long as peak levels are avoided and effective plasma levels are obtained, any enteral administration may meet the requirements.

[0094] The taxane and ritonavir (or other P-gp inhibitor) may be administered simultaneously. It will be appreciated that simultaneous administration may include administration of separate pharmaceutical formulations. For example, one pharmaceutical formulation suitable for oral administration comprises a taxane and another pharmaceutical formulation comprises ritonavir (or other P-gp inhibitor). Preferably, the pharmaceutical formulation comprising ritonavir (or other P-gp inhibitor) is also administered orally. It will be appreciated that simultaneous administration may include a pharmaceutical formulation comprising both a taxane and ritonavir (or other P-gp inhibitor). As used herein, simultaneous means administration of the taxane or ritonavir (or other P-gp inhibitor) within, for example, about 20 minutes, more preferably within 15 minutes, more preferably within 10 minutes, even more preferably within 5 minutes, and most preferably within 2 minutes of ritonavir (or other P-gp inhibitor) or taxane. Typically, it is preferred that oral administration of ritonavir (or other P-gp inhibitor) is performed simultaneously with oral administration of the taxane, as this provides optimal compliance for self-administration by the subject receiving treatment.

[0095] Alternatively, the taxane and ritonavir (or other P-gp inhibitor) can be administered separately and / or sequentially from each other, preferably within about 60 minutes of each other. When they are administered separately, ritonavir (or other P-gp inhibitor) is preferably administered before the taxane, and more preferably within about 60 minutes before the administration of the taxane.

[0096] The recommended dose of taxanes (such as docetaxel) may be 75 mg / m every 3 weeks. 2 With 100mg / m 2 The recommended dose for non-small cell lung cancer, breast cancer, gastric cancer, head and neck cancer, or prostate cancer may be 75 mg / m every 3 weeks. 2 The recommended dose is also 35 mg / m per week. 2 Tumor tissue taxane exposure levels may be defined herein as the area under the curve obtained when a taxane is administered intravenously and may correspond to an effective standard of care treatment for a taxane. It should be understood that this may not define the actual taxane level of the tissue, as taxanes are measured in plasma. Standard of care treatment for a taxane as used herein may be defined as intravenous administration of a recommended dose of a taxane.

[0097] The area under the curve (AUC; ng*h / mL) is determined within the first 48 hours after administration of the taxane, during which the taxane concentration in plasma can be measured at several time points and the surface of the area under the curve can be calculated from the plotted values. Plasma levels of taxanes can be measured by methods known in the art (Hendrikx et al. J. Chrom. B [Journal of Chromatography B], 2011), which may include liquid chromatography and mass spectrometry. Plasma is a blood component and it will be appreciated that in addition to measuring taxanes in plasma, levels of taxanes can also be measured in whole blood or serum. Taxane measurements, such as peak levels and the area under the plasma concentration-time curve (referred to herein as the area under the curve (AUC)) are defined relative to (blood) plasma, but can be readily recalculated to the corresponding peak levels in whole blood or serum. For example, the AUC may be in the range of 500-2500 ng·h / mL, such as at least 500 ng·h / mL, at least 600 ng·h / mL, at least 800 ng·h / mL, at least 1000 ng·h / mL, or at least 1200 ng·h / mL. For example, the AUC may be at most 2500 ng·h / mL, at most 2250 ng·h / mL, at most 2000 ng·h / mL, at most 1800 ng·h / mL, at most 1700 ng·h / mL, or at most 1500 ng·h / mL. For example, the AUC may be in the range of 800-1400 ng·h / mL. In this article, with respect to the plasma concentration-time curve of the taxane, the area under the curve or AUC are used interchangeably and refer to the area under the curve (ng·h / mL) within the first 48 hours after administration of the taxane. For example, these doses can be achieved by orally administering 50 mg of a taxane (such as docetaxel) once a week in two doses on one day (eg, 30 mg in the morning and 20 mg in the evening).

[0098] Preferably, a taxane or ritonavir (or other P-gp inhibitor) as described herein for use according to the invention is provided, wherein the cancer is a solid tumour. Preferably, the use of a taxane or ritonavir is a use wherein the solid tumour is non-small cell lung cancer, gastric cancer, breast cancer, head and neck cancer or prostate cancer. The solid tumours are preferred because taxanes (such as docetaxel) have been shown to be highly effective in these cancers.

[0099] Most preferably, the cancer is prostate cancer. Treatment of prostate cancer may involve the use of hormone therapy, such as androgen deprivation therapy. Prostate cancer may not respond to hormone therapy, and this prostate cancer is called hormone-refractory prostate cancer (HRPC). Prostate cancer may respond to hormone therapy, and this prostate cancer is called hormone-sensitive prostate cancer (HSPC). Such patients may also have metastasis, or metastasis may occur during treatment. Such cancers are called mHRPC or mHSPC (m indicates metastasis). Prostate cancer treatment may include castration. In any case, prostate cancer generally involves testosterone in the body being reduced to very low levels. As shown in the examples, relative to patients with solid tumors that are not mCRPC, in patients with mCRPC, the clearance rate of taxanes measured in plasma is significantly increased. Testosterone levels in such patients are very low. Relative to prostate cancer patients who receive intravenously administered taxanes in the late stage of the disease, patients who receive intravenously administered taxanes and androgen deprivation therapy in parallel in the early stage of the disease experience more toxicity. Thus, in prostate cancer treatment involving the use of hormone therapy (which involves androgen inhibitors), it may also be expected that taxane plasma levels will be reduced by increasing the clearance of taxanes, but such increased clearance may need to be established first after the initiation of hormone therapy. Thus, the dose of taxane and / or ritonavir (or other P-gp inhibitor) may be adjusted early in the treatment of prostate cancer to compensate for the relatively lower plasma levels in such patients compared to patients with mCRPC. Conversely, it may be necessary to first establish the plasma level of the taxane, for example by administering a first oral dose of a combination of a taxane according to the invention and ritonavir (or other P-gp inhibitor) and determining the plasma concentration of the taxane (such as AUC) to confirm that the same dose as that suitable for mCRPC can be administered. In any case, a dose suitable for mCRPC may also be suitable for HSPC, HRPC, mHRPC, mHSPC or CRPC (i.e., non-metastatic). In a preferred embodiment, a dose suitable for mCRPC is also selected for the treatment of mHSPC.

[0100] In preferred embodiments, the prostate cancer is metastatic castration-resistant prostate cancer (mCRPC).

[0101] The dosing interval and / or dose of the taxane and / or ritonavir (or other P-gp inhibitor) can be selected to allow for providing a desired taxane exposure level in the tumor tissue that is comparable or at least comparable to the standard of care treatment of docetaxel. For example, docetaxel or ritonavir (or other P-gp inhibitor) can be used in a combination therapy where docetaxel is administered orally at a weekly dose where the docetaxel exposure level is comparable to the standard of care treatment, resulting in an area under the curve of 600-1800 ng·h / mL, more preferably 1000-1500 ng·h / mL.

[0102] In some embodiments, the weekly dose of ritonavir and / or taxane can be divided so that the subject uses a first dose in the morning, for example, once a week, and a second dose in the evening. This may have the effect of reducing the peak level of one or more drugs in the plasma, which may help reduce side effects. It may also increase the systemic exposure time of the drug. For example, ritonavir and / or taxane can be administered once a week and twice a day, which means that on one day of the week, ritonavir and / or taxane are administered twice, for example within an 8-16 hour interval. Therefore, ritonavir and / or taxane can be administered three times a day, twice a day, or once a day, once every two days, once a week, once every two weeks, once every three weeks, or any other suitable dosing interval. Combinations of these dosage regimens can also be used, for example, ritonavir and / or taxane can be administered once a week or once every two weeks or once every three weeks and twice a day.

[0103] For example, in an embodiment, docetaxel is orally administered at a weekly dose of 50 mg for the treatment of solid tumors. Such administration is preferably performed on a weekly and twice-a-day schedule. Thus, provided herein is a weekly and twice-a-day schedule for the treatment of solid tumors, for the treatment of solid tumors, wherein docetaxel is administered one day a week, the first dose administered is 30 mg of docetaxel with 100 mg of ritonavir, and the second dose administered is 20 mg of docetaxel with 100 mg of ritonavir.

[0104] In another embodiment, for the treatment of solid tumors, docetaxel is orally administered at a weekly dose of 40 mg. Such administration is preferably performed on a weekly and twice-a-day schedule. Thus, provided herein is a weekly and twice-a-day schedule for the treatment of solid tumors, for the treatment of solid tumors, wherein docetaxel is administered one day a week, the first dose administered is 20 mg of docetaxel with 200 mg of ritonavir, and the second dose administered is 20 mg of docetaxel with 100 mg of ritonavir.

[0105] In one embodiment, a weekly and twice-a-day schedule for treating cancer is provided, wherein docetaxel is administered one day a week, the first dose is 30 mg of docetaxel with 200 mg of ritonavir, and the second dose is 20 mg of docetaxel with 200 mg of ritonavir. In another embodiment, a weekly and twice-a-day schedule for treating cancer is provided, wherein docetaxel is administered one day a week, the first dose is 20 mg of docetaxel with 200 mg of ritonavir, and the second dose is 20 mg of docetaxel with 200 mg of ritonavir. In yet another embodiment, a weekly and twice-a-day schedule for treating cancer is provided, wherein docetaxel is administered one day a week, the first dose is 20 mg of docetaxel with 100 mg of ritonavir, and the second dose is 20 mg of docetaxel with 100 mg of ritonavir. In another embodiment, a once-weekly and twice-daily schedule for treating cancer is provided, wherein docetaxel is administered one day a week, the first dose administered is 20 mg of docetaxel with 200 mg of ritonavir, and the second dose administered is 20 mg of docetaxel with 100 mg of ritonavir.

[0106] In a further embodiment, docetaxel is orally administered at a weekly dose of 50 mg to treat mCRPC. This administration is preferably performed on a weekly and twice-a-day schedule. It may be necessary to adjust the dose of ritonavir for mCRPC patients so that a defined AUC can be obtained. Therefore, a weekly and twice-a-day schedule for treating mCRPC is provided herein for the treatment of cancer, wherein docetaxel is orally administered on the same day, the first dose of 30 mg of docetaxel and 200 mg of ritonavir, and the second dose of 20 mg of docetaxel and 100 mg of ritonavir.

[0107] The taxane level in the subject can be controlled prior to treatment and / or monitored and controlled during treatment with an oral administration of a taxane and ritonavir (or other P-gp inhibitor). Such monitoring and control can also be performed alternatively (or additionally) by measuring the taxane in plasma. Such monitoring and control can also be performed by monitoring side effects. Taxane clearance in a subject may vary for unknown reasons. Therefore, monitoring the taxane level in a subject during treatment allows the taxane dose to be adjusted to maintain an appropriate level of taxane in the subject. Monitoring side effects also helps in this regard. When the area under the curve is determined, a suitable dose of ritonavir (or other P-gp inhibitor) and a taxane combination that can achieve a desired tumor tissue exposure level can be determined. For example, in a first adjustment, the increase in the area under the curve may be too high, resulting in undesirable side effects. After a second adjustment, a defined area under the curve can be achieved, thereby providing a defined tumor tissue exposure level with significantly reduced side effects.

[0108] Therefore, the present invention may include the following steps:

[0109] - Administration of a combination of a taxane and ritonavir (or other P-gp inhibitor);

[0110] - Determining the plasma level of a taxane in a subject;

[0111] -optionally, comparing the level of the taxane to a reference level;

[0112] - determining the taxane dose for subsequent administration of a combination of ritonavir (or other P-gp inhibitor) and a taxane; and

[0113] - Subsequent combination administration of ritonavir (or other P-gp inhibitor) and a taxane.

[0114] By measuring the plasma level of the taxane after the first administration, it can be confirmed that the selected dose (of both ritonavir (or other P-gp inhibitor) and the taxane) for the first administration is the appropriate dose. Conversely, when the plasma level is too high or too low, the dose of the subsequent combination of ritonavir (or other P-gp inhibitor) and the taxane can be adjusted. The dose of ritonavir (or other P-gp inhibitor) or the taxane, or the dose of both ritonavir (or other P-gp inhibitor) and the taxane can be adjusted. Therefore, the dose of ritonavir (or other P-gp inhibitor) can be kept the same at the first administration and subsequent administrations, and the dose of the taxane can be adjusted to offset any increase or decrease in the plasma level of the taxane. Therefore, in this treatment method involving measuring the plasma level of the taxane, ritonavir (or other P-gp inhibitor) is administered at a predetermined dose. In addition, the dose of the taxane can be kept the same at the first administration and subsequent administrations, and the dose of ritonavir (or other P-gp inhibitor) can be adjusted to offset any increase or decrease in the plasma level of the taxane. Preferably, the dose of the taxane is adjusted to eradicate tumor cells.

[0115] Thus, throughout the treatment period, at least the dose of the taxane in the subsequent combination of ritonavir (or other P-gp inhibitor) and taxane may be sufficient to achieve a desired tumor tissue taxane exposure level that may be comparable or at least comparable to standard of care treatment with taxanes. Preferably, the method for treating cancer comprises multiple administrations of a combination of ritonavir (or other P-gp inhibitor) and a taxane, wherein the level of the taxane is determined after each administration in order to determine the dose of the taxane for administration of the subsequent combination of ritonavir (or other P-gp inhibitor) and taxane. Thus, when the level of the taxane in the subject increases compared to the reference level, the dose of the taxane is reduced, and wherein when the level of the taxane decreases during the treatment period compared to the reference level, the dose of the taxane is increased compared to the previous dose administered.

[0116] In another embodiment, the present invention may include the following steps:

[0117] - Determining the expression of ritonavir (or other P-gp inhibitor) in a subject;

[0118] -optionally, comparing the expression of ritonavir (or other P-gp inhibitor) to a reference level;

[0119] - Determine the dose of ritonavir (or other P-gp inhibitor) based on the expression level of ritonavir measured in the subject;

[0120] - administering a determined dose of ritonavir (or other P-gp inhibitor) in combination with a taxane,

[0121] The dose of the taxane is sufficient to achieve a level of tumor tissue taxane exposure comparable to standard of care taxane therapy.

[0122] Since the expression of ritonavir (or other P-gp inhibitor) in a subject may have an effect on the dose of taxane administered to obtain adequate exposure levels, determining the expression of ritonavir (or other P-gp inhibitor) may have the advantage that possible variations between subjects can be taken into account. This may be done before the start of treatment. The expression of ritonavir (or other P-gp inhibitor) in a subject may be determined by any known means, but may also be determined by measuring the plasma level of ritonavir (or other P-gp inhibitor) or other indirect methods. By knowing the appropriate dose of ritonavir (or other P-gp inhibitor) before the start of treatment, the desired docetaxel exposure level in the subject can be obtained immediately from the start of treatment. Therefore, in a preferred embodiment, in the method according to the present invention, the step of determining the expression of ritonavir (or other P-gp inhibitor), followed by the optional step of comparing and the step of determining the dose are performed before the first administration of the combination of ritonavir (or other P-gp inhibitor) and taxane.

[0123] In a further embodiment, a kit for use in the methods and uses as described herein for a combination of a taxane and a P-gp inhibitor (such as ritonavir or elacridar) is provided. In one embodiment, a kit is provided, comprising a pharmaceutical composition containing a taxane for oral administration and a pharmaceutical composition containing a P-gp inhibitor (such as ritonavir or elacridar). In another embodiment, a kit is provided, comprising a pharmaceutical composition containing a taxane for oral administration and a pharmaceutical composition containing a P-gp inhibitor (such as ritonavir or elacridar), wherein the kit is used to treat solid tumors, particularly non-small cell lung cancer, gastric cancer, breast cancer, head and neck cancer or prostate cancer, more particularly mCRPC. In yet another embodiment, a kit is provided, comprising a pharmaceutical composition containing a taxane and a pharmaceutical composition containing a P-gp inhibitor (such as ritonavir or elacridar), wherein the kit is used in a combination therapy as defined in any one of the methods and uses according to the invention as described herein.

[0124] The pharmaceutical composition of the present invention may comprise a taxane or a pharmaceutically acceptable salt or ester thereof and / or ritonavir (or other P-gp inhibitors) or a pharmaceutically acceptable salt or ester thereof, together with any pharmaceutically acceptable carrier, adjuvant or vehicle.

[0125] As used in the specification, clauses, and clauses of the appended claims of the present invention, the singular forms "a", "an", and "the" are used interchangeably and are intended to include the plural forms as well, and fall within each meaning unless the context clearly indicates otherwise. Also as used herein, "and / or" refers to and encompasses any and all possible combinations of one or more of the listed items, as well as the lack of a combination when interpreted in the alternative ("or"). As used herein, the term "about" will be understood by one of ordinary skill in the art and will vary to some extent depending on the context in which it is used. If a term is used that is unclear to one of ordinary skill in the art, then in the context in which the term is used, "about" will mean up to plus or minus 10% of the particular term.

[0126] Examples

[0127] Overview

[0128] In the first study, the protein expression level of P-gp in parental and docetaxel-resistant prostate cancer cell lines (DU-145, DU-145DOC10, 22Rv1 and 22Rv1 DOC8) was evaluated by Western blot analysis. This study consists of 5 parts. In the first part, the protein expression level of P-gp in parental and docetaxel-resistant cell lines was evaluated by Western blot analysis. Next, the anticancer activity of cabazitaxel in monotherapy for four cell lines was evaluated using a 3D colony formation assay to determine the concentration for subsequent combination studies. The anticancer activity of different following dual drug combinations was studied in an 8*2 matrix layout (combining 8 concentrations of the first compound with 2 concentrations of the second compound): docetaxel + elida; docetaxel + ritonavir; and cabazitaxel + ritonavir. Colony counting based on image analysis was used as a readout. Data analysis was performed using the Bliss independence method to identify additive / synergistic / antagonistic effects. A significant upregulation of P-gp (MDR1) protein expression was observed in the resistant cell lines compared to the corresponding parental lines. This is consistent with the results of a previous study, in which both resistant cell lines showed overexpression of mdr-1 mRNA as determined by RNA-Seq.

[0129] Ritonavir and elacridar have been shown to inhibit P-gp and were tested in combination with docetaxel to examine their docetaxel resistance reversal effects. A concentration of 31.6 μM ritonavir reduced the relative IC of docetaxel to 50 The value decreased from 0.219 μM to 0.0026 μM (84-fold), and a strong synergistic effect was observed at intermediate concentrations of docetaxel. 100 μM of ritonavir completely inhibited tumor colony formation, and no additional effect was observed in combination with docetaxel.

[0130] For the combination of docetaxel + / - elacridar, a synergistic effect was observed in the docetaxel-resistant cell lines 22Rv1 DOC8 and DU-145DOC10, but not in the parental cell line DU-145. Thus, the effects of ritonavir observed in previous studies could be reproduced by elacridar, strongly suggesting that inhibition of P-gp is responsible for the resistance-reversing effect.

[0131] Next, a 3D colony formation assay was used to determine the IC 50 The anticancer activity of cabazitaxel in monotherapy against four cell lines was investigated at 24-hour concentrations. Cabazitaxel inhibited tumor cell growth in a concentration-dependent manner in all four cell lines, with higher IC in docetaxel-resistant cell lines compared with the parental cell lines. 50 For 22Rv1DOC8, a relative IC of 14.5-fold was observed compared to 22Rv1 50 Compared with DU-145, IC 50 The shift in values ​​was 2.7-fold. Therefore, resistance to docetaxel also resulted in lower sensitivity to cabazitaxel.

[0132] For the combination of cabazitaxel + / - ritonavir, a strong synergistic effect was observed in the docetaxel-resistant cell line 22Rv1 DOC8, whereas no or only low synergistic effects were observed in the parental cell line and DU-145DOC10. In 22Rv1 DOC8, ritonavir completely reversed resistance to cabazitaxel.

[0133] Experimental methods

[0134] For single-agent efficacy experiments, the main stock solution of cabazitaxel was prepared by dissolving the compound powder in DMSO at a concentration of 10mM. A working stock solution of 0.1mM (330 times the highest tested concentration) was thus prepared. Small aliquots of this solution were stored at -20°C. On each day of the experiment, frozen aliquots of the working stock solution were thawed before and during treatment and stored at room temperature. First, serial half-log dilutions of the working stock solution were prepared in DMSO. These dilutions were then diluted 1:22 into the cell culture medium in the intermediate dilution plate. Finally, 10 μl taken out from the intermediate dilution plate was transferred to 140 μl / well of the final assay plate. Therefore, the DMSO working stock solution was diluted 1:330, and the DMSO concentration in the assay was 0.3% v / v.

[0135] For the combination experiment, the working stock solution of docetaxel, ritonavir, elacrida and cabazitaxel was prepared in DMSO at a concentration of 660 times the highest test concentration used. Small aliquots of this stock solution were stored at -20 ° C. On each day of the experiment, before and during the treatment, the frozen aliquots of the working stock solution were thawed and stored at room temperature. First, a 1:2 dilution of the 660-fold concentrated working stock solution was performed in DMSO (in the case of monotherapy control), or an equal amount of compound working stock solution was mixed (in the case of drug combination). Then, different dilutions of these 330-fold concentrated solutions were performed in DMSO to obtain an 8*2 matrix combination layout. In the intermediate dilution plate, the DMSO dilution was further diluted to 1:22 into the cell culture medium (IMDM supplemented with 20% (v / v) bovine serum, 50 μg / ml gentamicin). Finally, 10 μl taken out from the intermediate dilution plate was transferred to 140 μl cells and culture medium in each well of the final assay plate. Therefore, DMSO dilutions for single and combination treatments were diluted 1:330 and the DMSO concentration in the assay was 0.3% v / v.

[0136] DU-145DOC10 was generated from DU-145, and 22Rv1 DOC8 was generated from 22Rv1. 22Rv1 was obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA), and DU-145 was obtained from the National Cancer Institute (NCI, Bethesda, MD, USA).

[0137] Tumor cell lines were grown at 37°C in a humidified atmosphere with 5% CO2 in RPMI 1640 culture medium (Biochrom) supplemented with 10% (v / v) fetal bovine serum and 50 μg / ml gentamicin. Docetaxel-resistant sublines were cultured in the presence of 8nM (22Rv1) or 10nM docetaxel (DU-145). Cells were routinely passaged once or twice per week and maintained in culture for up to 20 generations. For determination, TrypLE cells were harvested and the percentage of viable cells was determined by a CASY TT cell counter (OMNI Life Science).

[0138] Colony formation assays were performed in 96-well format using ultra-low attachment plates. For each test, cells were prepared and assay plates were prepared as follows: each test well contained a layer of semi-solid culture medium with tumor cells (50 μl) and a second layer of culture supernatant with or without test compound (100 μl). The cell layer consisted of 2·10 3 Until March 10 3The cells were inoculated in 50 μl / well cell culture medium (IMDM supplemented with 20% (v / v) fetal bovine serum, 50 μg / ml gentamicin and 0.4% (w / v) agar). After 24 h, the soft agar layer was covered with 90 μl of the same culture medium without agar, and 10 μl of control culture medium or the test compound after being serially diluted in DMSO and transferred to the cell culture medium was added, and left on the cells during the experiment (continuous exposure, 100 μl drug coverage). Each plate includes six untreated control wells and drug treatment groups. The values ​​of duplicates are obtained by testing a single value of each condition on a plate. The culture was incubated in a humidified atmosphere for 13 days at 37 ° C and 7.5% CO2, and the colony growth was closely monitored using an inverted microscope. During this period, tumor growth resulted in the formation of a diameter>50 μm (area>2000 μm 2 ) colonies. At maximum colony formation, viable colonies were stained with a sterile aqueous solution of 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride (INT, 1 mg / ml, 25 μl / well) for 48 hours, and colony counting was performed using an automated image analysis system (CellInsight NXT, ThermoScientific or Bioreader 5000V-alpha, BIO-SYS GmbH).

[0139] Results and Discussion

[0140] like Figure 1 As shown, acquired resistance was observed in DU-145 prostate cancer cells exposed to docetaxel for 3 months, as shown by IC 50 The drug resistance of the cells was confirmed in the 3D culture (colony formation assay) device. The resistance to docetaxel was more obvious in the 2D device (21-fold) than in the 3D device (3.3-fold).

[0141] like Figure 2 As shown, acquired resistance was observed in 22Rv1 prostate cancer cells exposed to docetaxel for 3 months, as shown by IC 50 The drug resistance of the cells was confirmed in the 3D culture (colony formation assay) device. Resistance to docetaxel was more pronounced in the 2D device (105-fold) than in the 3D device (42-fold).

[0142] like Figure 3As shown, high P-glycoprotein (P-gp protein) overexpression was observed in docetaxel-resistant prostate cancer cells. Very high P-gp protein overexpression was observed in DU-145DOC10 cells. P-pg protein overexpression was also observed in 22RV1 DOC8 cells. In addition, high P-gp (MDR-1) mRNA overexpression was observed in DU-145DOC10 cells (3287 times compared to the parent) and 22Rv1 DOC8 cells (2772 times overexpression). 22RV1 DOC8 cells express less P-gp protein than DU-145DOC10, even though they are much more resistant to docetaxel (134 times and 22 times, respectively, under 2D culture conditions). This also suggests that de novo resistance to taxanes may exist in patients with naturally higher expression or overexpression of P-pg protein.

[0143] like Figure 4 As shown, in two resistant cell lines, DU-1245DOC10 and 22Rv1DOC8, the most upregulated gene was ABCB1 (P-glycoprotein) (3287-fold in DU145DOC10 and 2773-fold in 22Rv1DOC8). This also suggests that de novo resistance to taxanes may exist in patients with naturally higher expression or overexpression of P-pg protein.

[0144] It is therefore concluded that docetaxel resistance in DU-145 and 22Rv1 prostate cancer cell lines is primarily driven by distinct gene expression and functional pathway responses. A degree of overlap was identified in the responses of the two cell lines, which may indicate a common resistance-associated mechanism. In both cell lines, P-glycoprotein was the most highly overexpressed gene.

[0145] Ritonavir is an inhibitor of P-glycoprotein. Figure 5 As shown in the table below, ritonavir reversed docetaxel resistance in castration-resistant DU-145DOC10 prostate cancer cells (colony formation assay). 10 μM ritonavir induced increased sensitivity of DU-145DOC10 resistant cells to docetaxel (IC 50 Addition of 10 μM ritonavir to the resistant cells resulted in their sensitivity (IC 50 =2.8 nM) and the sensitivity of the parental cells (IC 50 =2.9 nM), demonstrating the reversal of drug resistance.

[0146]

[0147] like Figure 6As shown, ritonavir and docetaxel act synergistically in docetaxel-resistant DU-145DOC10 prostate cancer cells (colony formation assay). 10 μM ritonavir induced increased sensitivity of DU-145DOC10 resistant cells to docetaxel (IC 50 The combination of 10 μM ritonavir and 3 nM docetaxel resulted in a strong synergistic effect in DU-145DOC10 resistant cells compared to parental cells.

[0148] like Figure 7 As shown in the table below, ritonavir also reversed docetaxel resistance in 22Rv1 DOC8 resistant prostate cancer cells. In resistant cells, a strong synergistic effect was observed in the case of a combination of 32 μM ritonavir and a moderate concentration of docetaxel (3.16 nM to 316 nM), demonstrating that ritonavir can reverse resistance.

[0149] 22Rv1 DOC8 Docetaxel Ritonavir <![CDATA[IC value in nM 50 value]]> - 202 32μM 3

[0150] like Figure 8 As shown, ritonavir and cabazitaxel induce a synergistic effect in parental DU-145 prostate cancer cells. Ritonavir inhibits the growth of DU145 at concentrations of 10 μM and higher. The combination of 10 μM ritonavir and 0.3 nM cabazitaxel has a synergistic effect in DU145 cells.

[0151] like Fig. 9 As shown, ritonavir and cabazitaxel induce a synergistic effect in docetaxel-resistant DU-145DOC10 prostate cancer cells. Ritonavir inhibits the growth of DU145 DOC10 at concentrations of 10 μM and higher. The combination of 10 μM ritonavir and 1 nM cabazitaxel has a synergistic effect in DU-145DOC10 resistant cells.

[0152] like Fig.10 As shown in the table below, ritonavir reversed cabazitaxel resistance in docetaxel-resistant DU145 DOC10 prostate cancer cells. 10 μM ritonavir induced increased sensitivity of DU-145DOC10 resistant cells to docetaxel (IC 50 Addition of 10 μM ritonavir to the resistant cells resulted in their sensitivity (IC 50 =0.6 nM) and the sensitivity of the parental cells (IC 50 =0.6 nM), demonstrating the reversal of drug resistance.

[0153]

[0154] like Fig.11As shown, ritonavir and cabazitaxel induce a synergistic effect in docetaxel-resistant 22Rv1 DOC8 prostate cancer cells. The combination of 32 μM ritonavir and 1, 3, and 10 nM cabazitaxel produced a synergistic effect in 22Rv1 DOC8 resistant cells.

[0155] like Fig.12 As shown in the table below, ritonavir reversed cabazitaxel resistance in docetaxel-resistant 22Rv1 DOC8 prostate cancer cells. 32 μM ritonavir induced increased sensitivity of 22Rv1 DOC8 resistant cells to docetaxel (IC 50 Addition of 32 μM ritonavir to resistant cells resulted in their sensitivity (IC 50 =0.7 nM) and the sensitivity of the parental cells (IC 50 =0.7 nM), demonstrating the reversal of drug resistance.

[0156]

[0157] like Fig.13 As shown in the table below, Elacrida reversed docetaxel resistance in castration-resistant DU-145DOC10 prostate cancer cells. 0.3 and 1 μM Elacrida induced increased sensitivity of DU-145DOC10 resistant cells to docetaxel (IC 50 Addition of 0.3 and 1 μM elacrida to resistant cells resulted in their sensitivity (IC 50 =1.9 and 1.6 nM) were almost the same as the sensitivity of the parental cells (IC 50 =1.1 nM), demonstrating the reversal of drug resistance.

[0158]

[0159] like Fig.14 As shown, Elacridar and docetaxel are synergistic in docetaxel-resistant DU-145DOC10 prostate cancer cells (colony formation assay). The combination of 0.3 or 10 μM Elacridar with 3 or 10 nM docetaxel resulted in a strong synergistic effect in DU-145DOC10 resistant cells. No synergistic effect was observed in the parental cells, DU-145 cells.

[0160] like Fig.15 As shown in the table below, Elacrida reversed docetaxel resistance in castration-resistant 22Rv1 DOC8 prostate cancer cells. 0.3 and 1 μM Elacrida induced increased sensitivity of 22Rv1 DOC8 resistant cells to docetaxel (IC 50 Addition of 0.3 and 1 μM eleclidin to the resistant cells resulted in their sensitivity (IC50 =1.4 and 1.3 nM) and the sensitivity of the parental cells (IC 50 =1.3 nM), demonstrating the reversal of drug resistance.

[0161]

[0162] The above embodiments are described by way of example only. Many other embodiments falling within the scope of the appended claims will be apparent to the skilled reader. Therefore, although the present invention has been described in conjunction with the preferred embodiments of the various drawings, it should be understood that other similar embodiments may be used, or that modifications or additions may be made to the described embodiments to provide the same functions of the present invention without departing from the present invention. Therefore, the present invention should not be limited to any single embodiment, but rather should be interpreted within the breadth and scope of the narrative according to the appended claims.

[0163] Any feature that has been described above with respect to any one aspect or embodiment of the invention is also hereby disclosed with respect to all other aspects and embodiments. Likewise, all combinations of two or more of the individual features or elements described above may be present in any aspect or embodiment. For the sake of brevity, not all possible features and combinations are described with respect to all aspects and embodiments, but they are expressly contemplated and hereby disclosed.

Claims

1. A method for treating cancer in a taxane-resistant patient, the method comprising administering simultaneously or sequentially an effective dose of a taxane and ritonavir or a pharmaceutically acceptable salt thereof.

2. A method for reversing taxane resistance in a patient, the method comprising administering an effective dose of ritonavir or a pharmaceutically acceptable salt thereof.

3. The method according to claim 2, wherein the method is for treating cancer, and wherein ritonavir or a pharmaceutically acceptable salt thereof and an effective dose of a taxane are administered simultaneously or sequentially.

4. The method of claim 1 or 3, wherein the cancer comprises a solid tumor.

5. The method of claim 1, 3 or 4, wherein the cancer is selected from the group consisting of gastric cancer, breast cancer, head and neck cancer, lung cancer and prostate cancer.

6. The method of claim 5, wherein the cancer is prostate cancer.

7. The method of claim 5, comprising determining whether the cancer is responsive to treatment by determining the responsiveness of the DU-145 or 22Rv1 cell line to effective doses of a taxane and ritonavir or a pharmaceutically acceptable salt thereof, administered simultaneously or sequentially.

8. The method according to any preceding claim, wherein ritonavir and / or the taxane are administered orally.

9. The method according to any preceding claim, wherein ritonavir and / or the taxane are administered intravenously.

10. The method according to any preceding claim, wherein the taxane is selected from the group consisting of docetaxel, cabazitaxel, a pharmaceutically acceptable salt or ester thereof, and combinations thereof.

11. The method according to any preceding claim, wherein the taxane is docetaxel or a pharmaceutically acceptable salt or ester thereof.

12. The method of any preceding claim, wherein ritonavir is administered in a weekly dose of about 50 mg to about 1200 mg.

13. The method of any one of claims 1-11, wherein ritonavir is administered in a daily dose of about 50 mg to about 1200 mg.

14. The method according to any preceding claim, wherein the taxane is administered at a weekly dose of about 30 mg to about 500 mg.

15. The method of any one of claims 1-13, wherein the taxane is administered at a daily dose of about 0.1 mg to about 100 mg.

16. The method of any one of claims 1 or 3-11, wherein ritonavir is administered at a daily dose of about 50 mg to about 1200 mg, and the taxane is administered at a daily dose of about 0.1 mg to about 100 mg, wherein the daily doses of ritonavir and the taxane may be taken at the same or different times of the day.

17. The method of any one of claims 1 or 3-11, wherein ritonavir is administered at a weekly dose of about 50 mg to about 1200 mg, and the taxane is administered at a weekly dose of about 30 mg to about 500 mg, wherein the weekly doses of ritonavir and the taxane may be taken on the same or different days.

18. A taxane for use in combination therapy with ritonavir or a pharmaceutically acceptable salt thereof to treat cancer in a taxane-resistant patient.

19. The taxane for use according to claim 18, wherein ritonavir or a pharmaceutically acceptable salt thereof is administered simultaneously or sequentially with the taxane.

20. The taxane for use according to claim 18 or 19, wherein the cancer comprises a solid tumor.

21. The taxane for use according to any one of claims 18-20, wherein the cancer is selected from the group consisting of gastric cancer, breast cancer, head and neck cancer, lung cancer and prostate cancer.

22. The taxane for use according to claim 21, wherein the cancer is prostate cancer.

23. The taxane for use according to claim 21, wherein the use comprises determining whether the cancer is responsive to treatment by determining the responsiveness of the DU-145 or 22Rv1 cell line to an effective dose of the combination therapy.

24. The taxane for use according to any one of claims 18 to 23, wherein ritonavir and / or the taxane are administered orally.

25. The taxane for use according to any one of claims 18 to 24, wherein ritonavir and / or the taxane is administered intravenously.

26. The taxane for use according to any one of claims 18-25, wherein the taxane is selected from the group consisting of docetaxel, cabazitaxel, a pharmaceutically acceptable salt or ester thereof, and a combination thereof.

27. The taxane for use according to any one of claims 18 to 26, wherein the taxane is docetaxel or a pharmaceutically acceptable salt or ester thereof.

28. The taxane for use according to any one of claims 18 to 27, wherein ritonavir is administered in a weekly dose of about 50 mg to about 1200 mg.

29. The taxane for use according to any one of claims 18 to 27, wherein ritonavir is administered in a daily dose of about 50 mg to about 1200 mg.

30. The taxane for use according to any one of claims 18-29, wherein the taxane is administered in a weekly dose of about 30 mg to about 500 mg.

31. The taxane for use according to any one of claims 18-29, wherein the taxane is administered in a daily dose of about 0.1 mg to about 100 mg.

32. The taxane for use according to any one of claims 18-27, wherein ritonavir is administered at a daily dose of about 50 mg to about 1200 mg, and the taxane is administered at a daily dose of about 0.1 mg to about 100 mg, wherein the daily doses of ritonavir and the taxane may be taken at the same or different times of the day.

33. The taxane for use according to any one of claims 18-27, wherein ritonavir is administered at a weekly dose of about 50 mg to about 1200 mg and the taxane is administered at a weekly dose of about 30 mg to about 500 mg, wherein the weekly doses of ritonavir and the taxane may be taken on the same or different days.

34. Ritonavir or a pharmaceutically acceptable salt thereof for use in reversing taxane resistance in a patient.

35. Ritonavir or a pharmaceutically acceptable salt thereof for use according to claim 34, for use in treating cancer in taxane-resistant patients, wherein ritonavir is administered simultaneously or sequentially with an effective dose of a taxane.

36. Ritonavir or a pharmaceutically acceptable salt thereof for use according to claim 35, wherein the cancer comprises a solid tumor.

37. Ritonavir or a pharmaceutically acceptable salt thereof for use according to claim 35 or 36, wherein the cancer is selected from the group consisting of gastric cancer, breast cancer, head and neck cancer, lung cancer and prostate cancer.

38. Ritonavir or a pharmaceutically acceptable salt thereof for use according to claim 37, wherein the cancer is prostate cancer.

39. Ritonavir or a pharmaceutically acceptable salt thereof for use according to claim 37, said use comprising determining whether the cancer is responsive to treatment by determining the responsiveness of the DU-145 or 22Rv1 cell line to effective doses of a taxane and ritonavir or a pharmaceutically acceptable salt thereof administered simultaneously or sequentially.

40. Ritonavir or a pharmaceutically acceptable salt thereof for use according to any one of claims 34 to 39, wherein ritonavir and / or the taxane are administered orally.

41. Ritonavir or a pharmaceutically acceptable salt thereof for use according to any one of claims 34 to 40, wherein ritonavir and / or the taxane are administered intravenously.

42. Ritonavir or a pharmaceutically acceptable salt thereof for use according to any one of claims 34-41, wherein the taxane is selected from the group consisting of docetaxel, cabazitaxel, a pharmaceutically acceptable salt or ester thereof, and a combination thereof.

43. Ritonavir or a pharmaceutically acceptable salt thereof for use according to any one of claims 34 to 42, wherein the taxane is docetaxel or a pharmaceutically acceptable salt or ester thereof.

44. Ritonavir or a pharmaceutically acceptable salt thereof for use according to any one of claims 34 to 43, wherein ritonavir is administered in a weekly dose of about 50 mg to about 1200 mg.

45. Ritonavir or a pharmaceutically acceptable salt thereof for use according to any one of claims 34 to 43, wherein ritonavir is administered in a daily dose of about 50 mg to about 1200 mg.

46. ​​Ritonavir or a pharmaceutically acceptable salt thereof for use according to any one of claims 35 to 45, wherein the taxane is administered in a weekly dose of about 30 mg to about 500 mg.

47. Ritonavir or a pharmaceutically acceptable salt thereof for use according to any one of claims 35 to 45, wherein the taxane is administered in a daily dose of about 0.1 mg to about 100 mg.

48. Ritonavir or a pharmaceutically acceptable salt thereof for use according to any one of claims 35 to 43, wherein ritonavir is administered at a daily dose of about 50 mg to about 1200 mg and the taxane is administered at a daily dose of about 0.1 mg to about 100 mg, wherein the daily doses of ritonavir and the taxane may be taken at the same or different times of the day.

49. Ritonavir or a pharmaceutically acceptable salt thereof for use according to any one of claims 35 to 43, wherein ritonavir is administered at a weekly dose of about 50 mg to about 1200 mg and the taxane is administered at a weekly dose of about 30 mg to about 500 mg, wherein the weekly doses of ritonavir and the taxane may be taken on the same or different days.

50. A method for sensitizing or resensitizing cells to taxanes in the treatment of cancer, the method comprising administering an effective dose of ritonavir or a pharmaceutically acceptable salt thereof.

51. The method of claim 50, wherein the taxane is selected from the group consisting of docetaxel, cabazitaxel, a pharmaceutically acceptable salt or ester thereof, and combinations thereof.

52. Ritonavir or a pharmaceutically acceptable salt thereof for use in sensitizing or resensitizing cells to taxanes in the treatment of cancer.

53. Ritonavir for use according to claim 52, wherein the taxane is selected from the group consisting of docetaxel, cabazitaxel, a pharmaceutically acceptable salt or ester thereof, and a combination thereof.

54. A kit comprising at least one pharmaceutical composition comprising a taxane and at least one pharmaceutical composition comprising a P-gp inhibitor, wherein the kit is for use in treating cancer in a taxane-resistant patient.

55. The kit of claim 54, wherein the taxane is selected from the group consisting of docetaxel, cabazitaxel, a pharmaceutically acceptable salt or ester thereof, and combinations thereof.

56. The kit of claim 54 or 55, wherein the P-gp inhibitor is selected from the group consisting of ritonavir, elacridar, and combinations thereof, or pharmaceutically acceptable salts thereof.

57. The kit of any one of claims 54-56, comprising instructions for simultaneous or sequential use of the pharmaceutical composition to treat cancer in a taxane-resistant patient.

58. A method for treating cancer, said treatment comprising a combination of a P-gp inhibitor and a taxane, said method comprising the steps of: Determination of ABCB1 (P-gp) expression in patients; Optionally, comparing the expression of ABCB1 (P-gp) to a reference level; Optionally, determining a dose of a P-gp inhibitor based on the expression level of ABCB1 (P-gp) determined in said subject; A combination of said P-gp inhibitor and said taxane is administered.

59. The method of claim 58, wherein the taxane is selected from the group consisting of docetaxel, cabazitaxel, a pharmaceutically acceptable salt or ester thereof, and combinations thereof.

60. The method of claim 58 or 59, wherein the P-gp inhibitor is selected from the group consisting of ritonavir, elacridar, and combinations thereof, or pharmaceutically acceptable salts thereof.

Citation Information

Patent Citations

  • Compositions for the treatment of neoplastic diseases

    WO2009027644A2

  • Cancer treatment using docetaxel by controlling peak plasma levels

    WO2020127606A1

  • Combination treatment for solid tumors using docetaxel and a CYP3a inhibitor

    WO2020127607A1